IMMU-22. COMBINATION IMMUNOTHERAPY WITH IDO1 INHIBITION ENHANCES TREATMENT EFFICACY IN MULTIPLE MODELS OF GLIOBLASTOMA MODEL

Progress in improving outcomes for glioblastoma (GBM) patients has been modest at best. Despite maximum surgical resection, radiotherapy (RT), and chemotherapy, the combination of which is considered the best treatment for GBM, median overall survival (OS) is only approximately 15 months. Treatment...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neuro Oncol
Egile Nagusiak: Ladomersky, Erik, Zhai, Lijie, Lauing, Kristen, Wu, Meijing, James, C David, Stupp, Roger, Wainwright, Derek
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2017
Gaiak:
Abstracts
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692829/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.480
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak